NCT04340362

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Vertex Pharmaceuticals Incorporated · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

Conditions

• Glomerulosclerosis, Focal Segmental

Interventions

Type	Name	Description
DRUG	VX-147	Tablets for oral administration.

Timeline

• Start date: 2020-06-08
• Primary completion: 2021-11-11
• Completion: 2021-12-09
• First posted: 2020-04-09
• Last updated: 2025-09-24
• Results posted: 2023-07-10

Locations

44 sites across 4 countries: United States, France, Puerto Rico, United Kingdom

Regulatory

• FDA-regulated drug study